Skip to content

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07363980
Acronym
COTIRA
Enrollment
4000
Registered
2026-01-23
Start date
2024-02-21
Completion date
2040-12-31
Last updated
2026-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anxiety Disorders, Atherosclerotic Ischemic Disease, Cardiovascular and Respiratory Disease, Cardiovascular Biomarkers, Cardiovascular (CV) Risk, Cardiovascular Disease, Cardiovascular Disease (CKD), Cardiovascular Disease (CVD) Risk Factors, COPD (Chronic Obstructive Pulmonary Disease), Depressive and Anxiety Disorders, Depressive Disorder, Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Lung Cancer (Diagnosis), Pulmonary Disease, Pulmonary Disease, Chronic Obstructive, Pulmonary Diseases or Conditions, Rheumatoid Arthritis

Keywords

Coronary Computed Tomography Angiography, Pulmonary function tests, Biobank, Faecal microbiome, Patient reported outcomes, Genome sequencing, RNA sequencing, Epigenom sequencing, Coronary Artery Calcium Score, Proteomics, Metabolomics, Lipidomics, Multi-omics, Patient-reported outcomes, Disease Activity Score-28 for Rheumatoid Arthritis, Deep phenotyping, Coronary plaque analysis

Brief summary

The Coronary Computed Tomography Angiography in Rheumatoid Arthritis study is part of the multinational, prospective, observational Autoimmunity and Atherosclerosis in Rheumatic Diseases cohort (https://atacc-rd.com) that includes comprehensive baseline and follow-up assessments at 3, 5, and 10 years. It comprises a main protocol and several optional modules, including a Cardiac Imaging Module, Biobanking Module, Pulmonary Module, and Anxiety and Depression Module. The study aims to advance understanding of cardiopulmonary and psychological comorbidities in rheumatoid arthritis, to improve early identification and management, and to enhance insights into underlying disease mechanisms-ultimately refining risk stratification and targeted prevention strategies. The study includes 4,000 patients with rheumatoid arthritis enrolled through the Cardiac Imaging Module in the main protocol. Participants undergo coronary computed tomography angiography, pulmonary function testing, physical examination, questionnaires, and biobanking, supplemented by genetic, proteomic, metabolomic, and microbiome profiling.

Detailed description

This prospective, observational study follows individuals with rheumatoid arthritis over time to understand how the disease and its treatment relate to cardiovascular, pulmonary, psychological, and biological outcomes. The study collects standardized clinical data from outpatient rheumatology clinics, complemented by advanced imaging, biological sample collection, and linkage to national health registries. Study Procedures and Visit Schedule Participants are enrolled during routine or ad-hoc outpatient visits. After informed consent, a baseline evaluation is performed, followed by standardized follow-up visits after approximately 3, 5, and 10 years (± 3-6 months). At baseline, demographic and lifestyle factors (age, sex, education, smoking, alcohol, physical activity, and family history) are recorded together with anthropometric measures (height, weight, waist circumference) and rheumatoid arthritis characteristics (serologic status, disease duration, erosive disease, and disease activity scores). Concomitant diseases and medications are documented, and vital signs and blood pressure are measured. Patient-reported outcomes include validated questionnaires on quality of life (Short Form 36, version 1), functional ability (Multidimensional Health Assessment Questionnaire), work productivity (Work Productivity and Activity Impairment - General Health), fatigue and pain visual analogue scales, physical activity (International Physical Activity Questionnaire - Short Form), and shortness of breath (University of California, San Diego Shortness of Breath Questionnaire). Laboratory results, including markers of inflammation and metabolic status, are obtained according to routine standards. Follow-up visits repeat these assessments to evaluate disease activity, lifestyle changes, and incident comorbidities. Events such as hospitalizations, procedures, and deaths are continuously updated through registry linkage, ensuring complete longitudinal follow-up. Registry Data Sources All participants are linked to national Danish health and administrative registries to enable comprehensive, long-term follow-up. The study integrates data from the National Patient Registry, the Danish Rheumatology Quality Database, the Civil Registration System, the Danish National Causes of Death Registry, the Western Denmark Heart Registry, the Danish Heart Registry, the Danish Stroke Registry, the Danish National Vascular Registry, the Danish National Database of Reimbursed Prescriptions, the Clinical Laboratory Information System, the Register of Laboratory Results for Research, and the Danish Research Institute for Economic Analysis and Modelling. Linkage across these registries allows continuous capture of clinical events, treatments, and vital status, ensuring complete longitudinal follow-up and verification of outcomes recorded during study visits. Governance The study is governed by an executive steering committee responsible for overall scientific direction, study design, resource allocation, and regulatory compliance. Supporting boards and advisory groups contribute to patient involvement, methodological quality, and international collaboration. Dedicated centers coordinate site operations, biobanking, cardiac imaging, and data analysis to ensure standardized procedures and data integrity across all participating sites. All procedures are conducted in accordance with Danish and European data-protection regulations, and data are stored and managed in secure systems compliant with the General Data Protection Regulation.

Interventions

None listed

Sponsors

Ellen Margrethe Hauge
Lead SponsorOTHER
University of Aarhus
CollaboratorOTHER
Aarhus University Hospital
CollaboratorOTHER
Independent Research Fund Denmark
CollaboratorINDUSTRY
Alfasigma S.p.A.
CollaboratorINDUSTRY
ATACC-RD consortium
CollaboratorUNKNOWN
The Danish Rheumatism Association
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Fulfill the ACR/EULAR-2010 criteria for rheumatoid arthritis * Attending or has attended at least one visit during the last two years in rheumatology outpatient clinic for diagnostic or monitoring purposes related to rheumatoid arthritis * Age 50-75 years

Exclusion criteria

* Diagnosed with overlapping systemic autoimmune diseases other than secondary Sjogren's syndrome * Active cancer * Prior coronary atherosclerotic symptoms as defined by myocardial infraction, percutaneous coronary intervention, or coronary artery bypass grafting * Allergy to radiocontrast agents * Estimated glomerular filtration rate (eGFR) \< 30 mL/min * BMI \> 35 kg/m2 * Persistent atrial fibrillation

Design outcomes

Primary

MeasureTime frameDescription
Number of participants with a first occurrence of any ischemic cardiovascular events, including MACE3, 5 and 10 yearsHospitalization for cerebrovascular disease (transient ischemic attack). Hospitalization for peripheral vascular disease. Hospitalization for peripheral vascular surgery. Cardiovascular death as defined by death from any of the following causes: Ischemic heart disease; Sudden cardiac death; Ventricular tachycardia; Other cardiac arrhythmias; Heart failure; Fatal ischemic stroke; Sudden undefined death; Unwitnessed or unknown cause of death. Hospitalization for non-fatal myocardial infarction, including hospitalization for PCI and CABG. Hospitalization for non-fatal ischemic stroke
Number of participants with all-cause death (all-cause mortality)3, 5 and 10 yearsDeath from any cause
Number of participants with a first occurrence of Major Adverse Cardiovascular Events (MACE)3, 5 and 10 years1. Cardiovascular death as defined by death from any of the following causes: Ischemic heart disease; Sudden cardiac death; Ventricular tachycardia; Other cardiac arrhythmias; Heart failure; Fatal ischemic stroke; Sudden undefined death; Unwitnessed or unknown cause of death 2. Hospitalization for non-fatal myocardial infarction, including hospitalization for PCI and CABG 3. Hospitalization for non-fatal ischemic stroke

Secondary

MeasureTime frameDescription
Number of participants with a occurrence of treatment for atrial fibrillation and flutter3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with sudden death3, 5 and 10 yearsSource of data: record and registry
Number of participants with cardiovascular death3, 5 and 10 yearsSource of data: record and registry
Coronary Artery Calcium Score (Agatston score)BaselineCoronary Artery Calcium Score (CACS), Agatston units. Minimum: 0. Maximum: No upper limit. Higher score indicates worse outcome (more coronary artery calcification).
The coronary artery plaque surface extent at baseline evaluated for the percent composition of non-calcified-, mixed-, and calcified plaquesBaselineQuantitative plaque measurement
Change in Coronary Artery Calcium Score (Agatston units) from baseline to 3 yearsBaseline and 3 yearsCoronary Artery Calcium Score (Agatston score), Agatston units. Change (Δ) in Coronary Artery Calcium Score (CACS) calculated as 3-year CACS minus baseline CACS. Minimum: No lower limit (negative). Maximum: No upper limit (positive). A positive change indicates increasing calcification (worse); a negative change indicates decreasing calcification (better).
The quantitative difference in coronary artery plaque surface extent from baseline to 3 years evaluated for the percent composition of non-calcified-, mixed-, and calcified plaquesBaseline and 3 yearQuantitative plaque measurement
Number of participants with a occurrence of hospitalization for cerebrovascular disease3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a first occurrence of hospitalization for non-fatal myocardial infarction3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization for non-fatal ischemic stroke3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization for peripheral vascular disease3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization for peripheral vascular surgery3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization for thromboembolic events as defined by deep vein thrombosis and pulmonary embolism3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of treatment for essential hypertension with/without complications3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of treatment for disorders of lipoprotein metabolism and other lipidemias3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of treatment for diabetes mellitus3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization for respiratory disease3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization or specialist-initiated treatment for interstitial pulmonary diseases3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization or specialist-initiated treatment for chronic lower respiratory diseases3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization or specialist-initiated treatment for anxiety disorders, including generalized anxiety disorder3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization or specialist-initiated treatment for a depressive episode or recurrent major depressive disorder3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of general practitioner-initiated treatment for anxiety disorders3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of general practitioner-initiated treatment for depression3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of referral to a psychologist or psychiatrist3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of infection with Mycobacterium tuberculosis3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of opportunistic infections3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a occurrence of hospitalization for infections (suspected/confirmed)3, 5 and 10 yearsSource of data: patient, record, registry
Proteomics concentrationsBaseline, 3, 5 and 10 yearsBlood sample
Metabolomics concentrationBaseline, 3, 5 and 10 yearsBlood and stool sample
Microbiome profile of stoolBaseline, 3, 5 and 10 yearsStool sample
Number of participants with a first occurrence of hospitalization for PCI3, 5 and 10 yearsSource of data: patient, record, registry
Genome-, epigenom-, and RNA sequencingBaseline, 3, 5 and 10 yearsBlood sample
Number of participants with a first occurrence of hospitalization for CABG3, 5 and 10 yearsSource of data: patient, record, registry
Number of participants with a first occurrence of treatment for stable angina pectoris3, 5 and 10 yearsSource of data: patient, record, registry

Countries

Denmark

Contacts

STUDY_CHAIREllen-Margrethe Hauge, MD, PhD

Aarhus University Hospital and Aarhus University

STUDY_DIRECTORDzenan Masic, MD, PhD

Aarhus University Hospital and Aarhus University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026